{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:27:58Z","timestamp":1792783678116,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of Heilongjiang","award":["H201442"],"award-info":[{"award-number":["H201442"]}]},{"name":"Science and technology project of the Heilongjiang Provincial Education Department","award":["12541450"],"award-info":[{"award-number":["12541450"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.biopha.2020.110824","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T19:45:28Z","timestamp":1607370328000},"page":"110824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice"],"prefix":"10.1016","volume":"133","author":[{"given":"Youbin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.biopha.2020.110824_bib0005","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke Statistics-2019 update: a report from the american heart association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.biopha.2020.110824_bib0010","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMra1606915","article-title":"Acute myocardial infarction","volume":"376","author":"Anderson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2020.110824_bib0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1871525714666161216100553","article-title":"Pathophysiology of myocardial infarction and acute management strategies","volume":"14","author":"Tibaut","year":"2017","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"issue":"7","key":"10.1016\/j.biopha.2020.110824_bib0020","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JIM.0000000000000232","article-title":"Acute complications of myocardial infarction in the current era: diagnosis and management","volume":"63","author":"Bajaj","year":"2015","journal-title":"J. Investig. Med."},{"issue":"2","key":"10.1016\/j.biopha.2020.110824_bib0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur. Heart J."},{"issue":"25","key":"10.1016\/j.biopha.2020.110824_bib0030","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1161\/CIRCULATIONAHA.107.748772","article-title":"Pharmacological intervention for prevention of left ventricular remodeling and improving prognosis in myocardial infarction","volume":"118","author":"Ishii","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.biopha.2020.110824_bib0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.biopha.2020.110824_bib0040","doi-asserted-by":"crossref","DOI":"10.1161\/HCQ.0000000000000032","article-title":"2017 AHA\/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures, Circulation","volume":"10","author":"Jneid","year":"2017","journal-title":"Cardiovascular Quality Outcomes"},{"issue":"8","key":"10.1016\/j.biopha.2020.110824_bib0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1753944718784536","article-title":"Sacubitril\/valsartan in cardiovascular disease: evidence to date and place in therapy","volume":"12","author":"Yandrapalli","year":"2018","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"11","key":"10.1016\/j.biopha.2020.110824_bib0050","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2020.110824_bib0055","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002551","article-title":"Prospective comparison of, plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study","volume":"9","author":"Zile","year":"2016","journal-title":"Circ. Heart Fail."},{"issue":"6","key":"10.1016\/j.biopha.2020.110824_bib0060","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jacbts.2017.08.001","article-title":"Cardioprotective effects of LCZ696 (Sacubitril\/Valsartan) after experimental acute myocardial infarction","volume":"2","author":"Ishii","year":"2017","journal-title":"JACC Basic Transl. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2020.110824_bib0065","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ejhf.474","article-title":"LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice","volume":"18","author":"Suematsu","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.biopha.2020.110824_bib0070","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijcard.2018.01.077","article-title":"Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction","volume":"258","author":"Kompa","year":"2018","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2020.110824_bib0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy, Circulation","volume":"8","author":"von Lueder","year":"2015","journal-title":"Heart Fail."},{"issue":"22","key":"10.1016\/j.biopha.2020.110824_bib0080","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","article-title":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials","volume":"97","author":"ACE Inhibitor Myocardial Infarction Collaborative Group","year":"1998","journal-title":"Circulation"},{"issue":"9335","key":"10.1016\/j.biopha.2020.110824_bib0085","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.biopha.2020.110824_bib0090","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"I. Valsartan in Acute Myocardial Infarction Trial, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110824_bib0095","unstructured":"(!!! INVALID CITATION !!!)."},{"issue":"3","key":"10.1016\/j.biopha.2020.110824_bib0100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/clinchem\/25.3.446","article-title":"Creatine kinase in serum: 6. Inhibition by endogenous polyvalent cations, and effect of chelators on the activity and stability of some assay components","volume":"25","author":"Szasz","year":"1979","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2020.110824_bib0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/icb.1975.8","article-title":"Purification, properties and kinetics of sheep and human renin substrates","volume":"53","author":"Skinner","year":"1975","journal-title":"Aust. J. Exp. Biol. Med. Sci."},{"issue":"9851","key":"10.1016\/j.biopha.2020.110824_bib0110","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"Prospective comparison of, the angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.biopha.2020.110824_bib0115","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Investigators","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"9722","key":"10.1016\/j.biopha.2020.110824_bib0120","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.biopha.2020.110824_bib0125","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/jch.13097","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema: a review of the literature","volume":"19","author":"Brown","year":"2017","journal-title":"J. Clin. Hypertens."},{"issue":"17","key":"10.1016\/j.biopha.2020.110824_bib0130","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jacc.2016.01.073","article-title":"Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction","volume":"67","author":"Westman","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.biopha.2020.110824_bib0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1161\/01.RES.0000117070.86556.9F","article-title":"B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation","volume":"94","author":"Kapoun","year":"2004","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.biopha.2020.110824_bib0140","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1073\/pnas.051625598","article-title":"A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy","volume":"98","author":"Kishimoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"updated-by":[{"DOI":"10.1016\/j.biopha.2021.112536","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000}}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220310179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220310179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:58:15Z","timestamp":1792720695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220310179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":28,"alternative-id":["S0753332220310179"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110824","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110824"}}